MedTrace Logo

Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection

NCT04553068 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1892

Last updated 2024-01-30

Study results available
· View outcomes & findings →

Summary

This study will evaluate whether EVO100 vaginal gel prevents the sexual transmission of CT and GC infection

Conditions

  • Sexually Transmitted Diseases
  • Gonorrhea
  • Chlamydia

Interventions

DRUG

EVO100

EVO100 vaginal gel

DRUG

Placebo

Placebo vaginal gel

Sponsors & Collaborators

  • Evofem Inc.

    lead INDUSTRY

Principal Investigators

  • Catherine Maher, PhD · Evofem Inc.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-15
Primary Completion
2022-07-28
Completion
2022-07-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04553068 on ClinicalTrials.gov